Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations in North Carolina

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specific Risk Awareness

For decades, general health and science information has served as the foundation for public understanding of medical conditions and treatment options. This broad educational context has empowered individuals to engage with their healthcare providers about prescription medications and potential side effects. Within this framework, the discussion of bisphosphonate therapies—such as Fosamax—has historically focused on their role in managing osteoporosis and maintaining bone density. As awareness of medication-associated risks has grown, the public health conversation has naturally expanded to include rare but serious adverse events linked to long-term use. One such concern involves the potential for osteonecrosis of the jaw, a condition affecting the jawbone that has been reported in some patients undergoing bisphosphonate therapy. This shift from general health education to specific risk awareness marks a critical transition. For individuals who have taken Fosamax and subsequently developed jaw-related complications, the focus moves from clinical understanding to legal and occupational considerations. In North Carolina, the statute of limitations imposes strict timeframes for filing claims related to such injuries. This pivot from broad health literacy to the practical realities of exposure and legal recourse underscores the importance of timely action for those affected.

Medical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In clinical studies, most patients who developed symptoms had relief after stopping the drug, but a subset experienced recurrence when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare, and fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Legal Considerations for North Carolina Patients: Statute of Limitations

From a medical risk perspective, the adequacy of warnings regarding Fosamax and ONJ is a key consideration. The prescribing information for Fosamax includes a section on warnings and cautions that specifically addresses ONJ, noting its association with bisphosphonate use and known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, patients and healthcare providers may need to weigh the benefits of fracture reduction against the rare but serious risk of ONJ, especially in those with additional risk factors such as dental procedures or cancer therapies. For affected patients in North Carolina, attorney-related considerations involve the statute of limitations for filing a claim related to Fosamax and ONJ. The statute of limitations is a legal time limit within which a lawsuit must be filed. In North Carolina, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is critical because the onset of ONJ symptoms can vary widely, from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), and the condition may be diagnosed months or years after exposure. Patients who develop ONJ after prolonged bisphosphonate use should be aware that the clock for legal action may start ticking from the date of diagnosis or when the link to Fosamax is reasonably suspected. Consulting with an attorney experienced in pharmaceutical litigation is advisable to determine the specific deadlines that apply to each individual case.

Timeline of Exposure and Harm: Key Considerations

The timeline between exposure to Fosamax and documented harm is variable. ONJ has been reported in patients taking bisphosphonates, and the risk may increase with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the incidence of ONJ is rare (https://pubmed.ncbi.nlm.nih.gov/42046648/), and not all patients exposed to Fosamax will develop the condition. For those who do, the harm is documented through clinical presentation, imaging, and biopsy, often following dental procedures or infections. The prescribing information advises discontinuation of Fosamax if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), and for patients requiring invasive dental work, stopping bisphosphonate treatment may reduce ONJ risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, the medical evidence indicates that Fosamax is associated with a rare risk of ONJ, with onset varying from days to months after starting the drug. The risk is higher in patients with certain dental procedures, cancer, or concomitant therapies. For North Carolina patients considering legal action, the statute of limitations is typically three years from discovery of the injury, making timely consultation with an attorney important. The adequacy of warnings in the prescribing information provides a basis for evaluating potential claims, but each case depends on individual circumstances, including the timeline of exposure and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Fosamax, is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. This means that if you developed osteonecrosis of the jaw (ONJ) after taking Fosamax, you typically have three years from the date of diagnosis or when you reasonably suspected the link to file a lawsuit. However, individual circumstances can affect this timeline, so consulting with an attorney is strongly recommended.

What are the known risk factors for developing ONJ from Fosamax?

Known risk factors for osteonecrosis of the jaw (ONJ) in patients taking bisphosphonates like Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures. The risk may also increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.